InvestorsHub Logo
Followers 16
Posts 1062
Boards Moderated 0
Alias Born 09/01/2019

Re: kalkid1 post# 35114

Friday, 02/05/2021 12:10:52 AM

Friday, February 05, 2021 12:10:52 AM

Post# of 44690
Yea, their specialty was Retirement homes and care, and they are using the NRXP deal to show in process.
GEM gets 7.5%+ $ of the NRXP deal when it closes and lots of stock.
GEM financed (1.3B, - 37% of OS) RLF for development of RLF-100, Trials and Patent.
GEM wants $$$ for their efforts... NRXP/RLFACER on the NASDAQ, IMO... Money talks, the RLF-100 Patent Rocks, SPAC wont balk.


VANSBIT, SEE THE RLFNRX PR 2-4-21.?.?.

https://moneymidnight.com/2021/02/rlftf-stock-relief-therapeutics-partner-neurorx-brpa-to-begin-phase-2-3-inhaled-zyesami-covid-19-study/



All development costs under the agreement are paid by Relief, providing NeuroRx with non dilutive development capital through drug approval"

Zyesami" Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM"